Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome

Obesity Research & Clinical Practice
Tetsuya KakumaHironobu Yoshimatsu

Abstract

Telmisartan has the dual ability to inhibit angiotensin II type 1 receptors and activate peroxisome proliferator-activated receptor gamma (PPAR), especially as a selective PPAR modulator that does not strongly promote adipogenesis for weight gain. Accordingly, Telmisartan is expected to provide beneficial effects for glucose and lipid metabolism without causing obesity. In the present study, we examined the effects of Telmisartan in patients with type 2 diabetes and metabolic syndrome. Thirty-two patients enrolled in this study were administered 40 mg per day of Telmisartan for 6 months. Telmisartan treatment significantly reduced systolic and diastolic blood pressure accompanied by induction of plasma renin activity (PRA) and reduction of serum aldosterone concentration and significantly decreased waist circumference, body mass index (BMI), and triglycerides (TG). In the 16 patients who did not take sulfonylurea, fasting plasma glucose (FPG) decreased and HbA1c significantly decreased from 3 months to 6 months. The results provide evidence that Telmisartan may improve glucose and lipid metabolism with the reduction in visceral fat mass in patients with type 2 diabetes and metabolic syndrome.:

References

Mar 1, 1992·The American Journal of the Medical Sciences·K FujimotoK Kurata
Aug 27, 2002·Journal of Hypertension·Lars H LindholmUNKNOWN LIFE study group
Jan 29, 2005·Diabetes Care·Sachiko HonjoHiroyuki Koshiyama
Jun 29, 2005·Circulation·Salim YusufUNKNOWN Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators
Jan 10, 2006·Drugs·Anna J Battershill, Lesley J Scott
Mar 28, 2006·The American Journal of Medicine·Theodore W Kurtz
Mar 14, 2007·Journal of Hypertension·Michio ShimabukuroTakeshi Shimabukuro
May 30, 2007·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·T InoueK Node
Aug 1, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Uta SyrbeYvonne Dörffel
Sep 23, 2008·Metabolism: Clinical and Experimental·Shinji MakitaMotoyuki Nakamura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.